Abstract 1355
Background
Surgery in cirrhotic patients in malignancy provokes scepticism and pessimism among clinicians due to mortality rates as high as 25% . In our study we looked at morbidity and mortality associated with these patients and present a positive perspective.
Methods
A data analysis of patients with cirrhosis, who underwent surgery for non-hepatic malignancy during the period January 2011 to December 2016, was done. Child Turcot Pugh (CTP) and Model for End stage Liver Disease (MELD) scores, various intraoperative parameters, perioperative morbidity (Clavien Dindo classification), mortality and hospital stay were recorded.
Results
40 patients with cirrhosis underwent surgery for non-hepatic malignancy. Emergency surgery was done in 6 patients. 26 patients were CTP grade A, 13 patients were grade B and 11 patients had grade C. Mean MELD score was 9.5 ±4.2. Overall mean operating time was 4.6 ±2.4 hours and blood loss was 305 ± 150 ml. In these patients, median blood transfusion requirement was 2 (1-5) PRBC. Overall morbidity was 26% but major morbidity (Clavien Dindo III) was seen in 5 patients (12.5%). Perioperative mortality occurred in 2 patients (5%). Patients who underwent surgery in emergency had more morbidity (n = 2,33%) and mortality (n = 1,16%) (p = <0.001).
Conclusions
In cirrhotic patients who undergo surgery for non-hepatic malignancy the factors associated with poor outcomes are emergency surgery, higher CTP grade and MELD score irrespective of type of malignancy. In these patients meticulous perioperative management can lead to excellent results and we need to shun negative attitudes while formulating a management plan for them.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
Saurabh Galodha.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
780 - The adipocyte suppresses the inhibitory role of hsa_circ_0000190 in the metastasis of breast cancer cells
Presenter: Xiu Chen
Session: Poster display - Cocktail
Resources:
Abstract
782 - CircASS1 suppressed the invasion and metastasis ability of breast cancer cell line by targeting gene ASS1 and harboring miR-4443
Presenter: Junchen Hou
Session: Poster display - Cocktail
Resources:
Abstract
916 - Ex-vivo drug sensitivity of primary breast cancer stems cell populations to potentiate therapeutic strategy for treatment resistant breast cancer
Presenter: Sourav Nandi
Session: Poster display - Cocktail
Resources:
Abstract
928 - Molecular Tumor Board (MTB): development of clinical pathways for precision medicine. Experiences of Center for Breast cancer at National cancer center, Korea
Presenter: In Hae Park
Session: Poster display - Cocktail
Resources:
Abstract
1274 - MicroRNA based immune response signature identifies poor prognostic subgroup within ER negative breast cancers
Presenter: Savitha Rajarajan
Session: Poster display - Cocktail
Resources:
Abstract
165 - The clinical efficacy of apatinib combined with Xeloda in advanced triple negative breast cancer
Presenter: YiHui Li
Session: Poster display - Cocktail
Resources:
Abstract
561 - Quality of life and psychosocial needs of metastatic breast cancer patients
Presenter: Tahir Mehmood
Session: Poster display - Cocktail
Resources:
Abstract
697 - TC-1 mediate the TBC1D3 oncogene induced migration of MCF-7 breast cancer cells
Presenter: Yong Shen
Session: Poster display - Cocktail
Resources:
Abstract
784 - RelB facilitates cell migration and invasion in breast cancer via MMP1 upregulation
Presenter: Mei Wang
Session: Poster display - Cocktail
Resources:
Abstract
921 - Re-challenging eribulin in patients with ER+HER2- metastatic breast cancer: A single-institution experience
Presenter: Junichiro Watanabe
Session: Poster display - Cocktail
Resources:
Abstract